Abstracts tagged "autoimmune diseases"

Abstract Number: 0996 • ACR Convergence 2021
The Stimulator of Interferon Genes (STING) Protects from Bone Loss Through Regulation of Tonic and Induced Type I Interferon Pathways
Susan MacLauchlan¹, Priyanka Kushwaha¹, Albert Tai², Jia (Sijia) Chen³, Catherine Manning¹, Katherine Fitzgerald⁴, Shruti Sharma² and Ellen Gravallese⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Tufts University School of Medicine, Boston, MA, ³Brigham and Women's Hospital, Cambridge, MA, ⁴University of Massachusetts Medical School, Worcester, MA, ⁵Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA
Background/Purpose: The intracellular DNA sensing Stimulator of Interferon Genes (STING) pathway is critical for detection of viral and bacterial pathogen DNA. Hyperactivating mutations in this…
Abstract Number: 1285 • ACR Convergence 2021
Major Determinants of Prolonged Remission in Systemic Lupus Erythematosus: Retrospective Study over a 41-Year Period
Goncalo Durao-Carvalho¹, Raquel Fernandez², Bethan Goulden³, Filipa Farinha⁴ and David Isenberg⁵, ¹Servico de Medicina Interna, Centro Hospitalar do Oeste – Unidade de Caldas da Rainha, Caldas da Rainha, Portugal, Caldas da Rainha, Portugal, ²Servicio de Medicina Interna, Hospital Universitario de Ourense, Ourense, Spain, ³Department of Rheumatology, University College London Hospitals, London, United Kingdom, ⁴Department of Rheumatology, University College London Hospitals and Centre for Rheumatology, University College London, London, United Kingdom, ⁵Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose: Disease activity is a major determinant of mortality whereas prolonged remission contributes to improving health outcomes in SLE patients (pts). Remission is thus a…
Abstract Number: 1516 • ACR Convergence 2021
Clinical Phenotypes and Treatment of Rheumatic Immune-Related Adverse Events from Checkpoint Inhibitors: A Retrospective Cohort of 112 Patients
Tiphaine Lenfant¹, Yuxuan Jin², Elizabeth Kirchner³, Pauline Funchain², Jung-Min Song², Moshe Ornstein², Laura Wood², Donald Eicher², Rula Hajj-Ali⁴, Leonard Calabrese² and Cassandra Calabrese⁵, ¹Institut Mutualiste Montsouris, Paris, France, ²Cleveland Clinic, Cleveland, OH, ³CCF, Cleveland, OH, ⁴Cleveland Clinic, Hunting Valley, OH, ⁵Cleveland Clinic Foundation, Cleveland Heights, OH
Background/Purpose: To describe a single center cohort of rheumatic immune related adverse events (irAEs) observed in patients treated with checkpoint inhibitor therapy (ICI) and to…
Abstract Number: 1602 • ACR Convergence 2021
Factors Associated with COVID-19 Vaccine Hesitancy in Rheumatology Outpatients in New York City
Medha Barbhaiya¹, Brandon Schneider², Jonah Levine¹, Huong Do¹, Caroline Siegel¹, Vivian Bykerk³, Candace Feldman⁴, Deanna Jannat-Khah¹ and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, ³Division of Rheumatology, Hospital for Special Surgery, New York City, NY, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: COVID-19 vaccination is particularly important for patients with systemic rheumatic diseases (SRDs), who may be at increased risk of infection with SARS-CoV-2 and of…
Abstract Number: 1759 • ACR Convergence 2021
An Analysis of Medication Responsiveness Based on Subtype and Race Within a Cohort of Cutaneous Lupus Erythematosus Patients
Emily Keyes¹, Anisha Jobanputra², Madison Grinnell³, Rui Feng⁴, Thomas Vazquez⁵, DeAnna Diaz⁶ and Victoria Werth⁷, ¹Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, ²Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, OMAHA, NE, ⁴University of Pennsylvania Department of Biostatistics, Philadelphia, PA, ⁵FIU Wertheim College of Medicine, Virginia Beach, VA, ⁶Philadelphia College of Medicine, Philadelphia, PA, ⁷Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Cutaneous lupus erythematosus (CLE) can present in association with or without concomitant SLE, and with skin manifestations varying by subtype – acute CLE, subacute…
Abstract Number: 0100 • ACR Convergence 2021
Safety of COVID-19 Vaccines After First Vaccination in Patients with Rheumatic Diseases in a Patient Reported Survey
Rebecca Hasseli¹, Bimba Franziska Hoyer², Hanns-Martin Lorenz³, Alexander Pfeil⁴, Jutta Richter⁵, Anne Regierer⁶, Tim Schmeiser⁷, Anja Strangfeld⁸, Reinhard Voll⁹, Andreas Krause¹⁰, Hendrik Schulze-Koops¹¹, Ulf Müller-Ladner¹² and Christof Specker¹³, ¹Justus-Liebig-University Giessen, Bad Nauheim, Germany, ²Universittsklinikum Schleswig-Holstein, Kiel, Germany, ³University Hospital Heidelberg Germany, Heidelberg, Germany, ⁴Friedrich Schiller University Jena, Jena, Germany, ⁵Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, ⁶German Rheumatism Research Center, Berlin, Germany, ⁷Private Practice, Cologne, Germany, ⁸Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁹Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany, ¹⁰Immanuel Hospital, Berlin, Germany, ¹¹Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ¹²JLU Giessen, Campus Kerckhoff, Dept. Rheum & Clin Immunol, Bad Nauheim, Germany, ¹³Evangelisches Krankenhaus, Kliniken Essen-Mitte, Essen, Germany
Background/Purpose: Among patients with rheumatic and musculoskeletal diseases (RMDs) and their treating physicians, concerns prevail about the effectiveness and safety of vaccination against COVID-19, especially…
Abstract Number: 0203 • ACR Convergence 2021
Chemoprophylaxis in Latent Tuberculosis Associated with Rheumatic Immune-mediated Diseases. Study of 240 Patients from a Single University Hospital
David Martinez-Lopez¹, Javier Rueda-Gotor¹, Joy Osorio-Chávez¹, Carmen Álvarez-Reguera¹, Virginia Portilla², Miguel Ángel gonzalez-Gay³ and Ricardo Blanco⁴, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Tuberculosis (TB) may be increased with biologic therapy (BT). Diagnosis and treatment of latent TB infection (LTBI) is the best strategy to prevent TB.…
Abstract Number: 0455 • ACR Convergence 2021
Abatacept Reverses Subclinical Arthritis in Patients with High-risk to Develop Rheumatoid Arthritis -results from the Randomized, Placebo-controlled ARIAA Study in RA-at Risk Patients
Juergen Rech¹, Mikkel Ostergaard², Koray Tascilar³, Melanie Hagen⁴, Larissa Valor Mendez⁴, Arnd Kleyer⁴, Gerhard Kroenke⁴, David Simon⁵, Verena Schoenau⁴, Axel Hueber⁶, Stefan Kleinert⁷, Xenofon Baraliakos⁸, Martin Fleck⁹, Andrea Rubbert-Roth¹⁰, Frank Behrens¹¹, David Kofler¹², Martin Feuchtenberger¹³, Michael Zaenker¹⁴, Reinhard Voll¹⁵, Cornelia Glaser¹⁶, Eugen Feist¹⁷, Gerd Burmester¹⁸, Kirsten Karberg¹⁹, Johannes Strunk²⁰, Juan D Cañete²¹, Esperanza Naredo²², Maria Filkova²³, Ladislav Senolt²⁴ and Georg Schett²⁵, ¹Friedrich-Alexander University (FAU) Erlangen-Nuernberg and Universitaetsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Germany, Erlangen, Germany, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark, ³Friedrich Alexander University of Erlangen Nuremberg, Universitaetsklinikum Erlangen Department of Medicine-3 Rheumatology and Immunology, Erlangen, Germany, ⁴Friedrich-Alexander University (FAU) Erlangen-Nuernberg and Universitaetsklinikum Erlangen, Medical Department 3, Rheumatology & Immunology, Erlangen, Germany, ⁵Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nrnberg, Erlangen, Germany, ⁶sozialstiftung-bamberg.de, Bamberg, Germany, ⁷Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany, ⁸Rheumazentrum Ruhrgebiet, Herne, Germany, ⁹Asklepios Klinikum Bad Abbach Klinik und Poliklinik für Rheumatologie/ Klin. Immunologie, Bad Abbach, Germany, ¹⁰Kantonspital St Gallen, St.Gallen, Switzerland, ¹¹Rheumatology & Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Fraunhofer Cluster Immune-Mediated Diseases (CIMD), Fraunhofer Cluster Immune-Mediated Diseases (CIMD), Frankfurt/Main, Germany, ¹²Division of Rheumatology and Clinical Immunology, Department I of Internal Medicine; University Hospital Cologne, Cologne, Germany, ¹³MED | BAYERN OST GmbH Fachbereich Rheumatologie, Burghausen, Germany, ¹⁴Immanuel Klinikum Bernau Herzzentrum Brandenburg, Bernau, Germany, ¹⁵Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany, ¹⁶Universitätsklinikum Freiburg Klinik für Rheumatologie und Klinische Immunologie, Freiburg, Germany, ¹⁷Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ¹⁸Charité University Medicine Berlin, Berlin, Germany, ¹⁹Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, ²⁰Krankenhaus Porz am Rhein GmbH Rheumaklinik, Köln (Porz), Germany, ²¹Rheumatology Department, Hospital Clinic, Barcelona, Spain, ²²Department of Rheumatology and Joint and Bone Research Unit, Hospital Fundación Jiménez Díaz and Autónoma University, Madrid, Spain, ²³Institute of Rheumatology and Connective Tissue Research Laboratory, Department of Rheumatology of First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ²⁴Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ²⁵Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany, Erlangen, Germany
Background/Purpose: Rheumatoid arthritis (RA) has a preclinical phase that is characterized by the presence of antibodies against citrullinated proteins (ACPA), subclinical arthritis and pain. ACPA…
Abstract Number: 0654 • ACR Convergence 2021
Assessing Provider Knowledge and Opinions of the 2017 Guidelines for Perioperative Management of Antirheumatic Medications in a Single Academic Center
Andrew Shaffer¹, Erica Mulcaire-Jones², Michael Battistone³, Jeremy Gililland⁴, Victor Carlson⁴, Joshua Zimmerman⁴, Kevin Lammert⁴ and Dorota Lebiedz-Odrobina⁴, ¹University of Utah, Sandy, UT, ²Intermountain Healthcare, Salt Lake City, UT, ³Salt Lake City VA, Salt Lake City, UT, ⁴University of Utah, Salt Lake City, UT
Background/Purpose: Guidelines for perioperative management of antirheumatic medications were released by the American College of Rheumatology (ACR) and American Association of Hip and Knee Surgeons…
Abstract Number: 1004 • ACR Convergence 2021
Manipulation of B7 Family Member Expression Demonstrates Synovial Macrophage Plasticity and Possible Future Targets for Treatment of Rheumatoid Arthritis
Annabelle Small¹, Katie Williams², Antonio Ferrante³, Malcolm Smith², Susanna Proudman⁴, Helen Weedon¹ and Mihir Wechalekar⁵, ¹Flinders University, Bedford Park, Australia, ²Flinders University, Adelaide, Australia, ³SA Pathology; University of Adelaide, Adelaide, Australia, ⁴University of Adelaide, Medindie, Australia, ⁵Flinders Medical Centre, Southern Adelaide Local Health Network, Bedford Park, Australia
Background/Purpose: Infiltration of monocyte-derived macrophages into the synovial tissue (ST) is a hallmark of rheumatoid arthritis (RA). These infiltrating cells lead to inflammation, local joint…
Abstract Number: 1301 • ACR Convergence 2021
Early Increase in Circulating Memory B Cells Portends Clinical Response to Treatment in Pooled Data from Three Phase III Trials of Belimumab
Ioannis Parodis¹, Alvaro Gomez², Julius Lindblom², Alexander Borg², Sharzad Emamikia² and Mariele gatto³, ¹Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden and Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden, ²Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ³Department of Rheumatology, University of Padua, Padua, Italy
Background/Purpose: Belimumab blocks soluble B cell activating factor (BAFF) and is the only to date approved targeted treatment for systemic lupus erythematosus (SLE). Identification of…
Abstract Number: 1517 • ACR Convergence 2021
Prevalence of Autoantibodies in Patients with Melanoma Who Develop Rheumatic Immune Related Adverse Events During Treatment with Immune Checkpoint Blockade
Sophia Weinmann¹, Amanda Eudy² and David Pisetsky¹, ¹Duke University Medical Center, Durham, NC, ²Duke University, Durham, NC
Background/Purpose: Patients with malignancy who develop rheumatic immune related adverse events (IRAEs) during immune checkpoint blockade (ICB) are commonly autoantibody negative. The change from chemotherapy…
Abstract Number: 1604 • ACR Convergence 2021
Perceptions About COVID-19 Vaccination Among Patients with Rheumatic Diseases Enrolled in a National Patient Registry
Maria I. Danila¹, Kelly Gavigan², Esteban Rivera², Michael George³, Jeffrey Curtis⁴, William Nowell² and Shilpa Venkatachalam², ¹University of Alabama at Birmingham, Birmingham, AL, ²Global Healthy Living Foundation, Upper Nyack, NY, ³University of Pennsylvania, Philadelphia, PA, ⁴Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: COVID-19 vaccine confidence is key to promoting vaccination efforts to mitigate the spread of COVID-19 among people with rheumatic diseases. The goal of this…
Abstract Number: 1767 • ACR Convergence 2021
CXCL5 Dampens Inflammation in Murine Lupus by Orchestral Suppression of Effector Cell Proliferation and Leukocyte Extravasation
Xiubo Fan¹, Chin Teck Ng¹, Dianyang Guo¹, Frances Lim¹, Annie Law², Julian Thumboo¹, William Hwang³ and Andrea Low¹, ¹Singapore General Hospital, Singapore, Singapore, ²Singhealth, Singapore, Singapore, ³National Cancer Centre Singapore, Singapore, Singapore
Background/Purpose: Systemic lupus erythematosus (SLE) is a potentially fatal autoimmune disease characterized by dysregulation of both innate and adaptive immunity. Current therapeutic options are limited,…
Abstract Number: 0101 • ACR Convergence 2021
Herpes Zoster Recombinant Zoster Vaccination Among Adults Age ≥50 Years with Immune Mediated Inflammatory Diseases in the United States
Jessica Leung¹, Tara Anderson¹, Kathleen Dooling¹, Fenglong Xie² and Jeffrey Curtis³, ¹Centers for Disease Control, Atlanta, GA, ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Persons with immune mediated Inflammatory diseases (IMIDs) are at increased risk of developing herpes zoster (HZ) and postherpetic neuralgia. In 2018, CDC recommended a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].